497 related articles for article (PubMed ID: 25617172)
21. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
Rejnmark L; Gosmanova EO; Khan AA; Makita N; Imanishi Y; Takeuchi Y; Sprague S; Shoback DM; Kohlmeier L; Rubin MR; Palermo A; Schwarz P; Gagnon C; Tsourdi E; Zhao C; Makara MA; Ominsky MS; Lai B; Ukena J; Sibley CT; Shu AD
Adv Ther; 2024 Jun; 41(6):2500-2518. PubMed ID: 38691316
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.
Winer KK; Sinaii N; Reynolds J; Peterson D; Dowdy K; Cutler GB
J Clin Endocrinol Metab; 2010 Jun; 95(6):2680-8. PubMed ID: 20392870
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.
Winer KK; Kelly A; Johns A; Zhang B; Dowdy K; Kim L; Reynolds JC; Albert PS; Cutler GB
J Pediatr; 2018 Dec; 203():391-399.e1. PubMed ID: 30470382
[TBL] [Abstract][Full Text] [Related]
24. PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.
Palermo A; Santonati A; Tabacco G; Bosco D; Spada A; Pedone C; Raggiunti B; Doris T; Maggi D; Grimaldi F; Manfrini S; Vescini F
J Clin Endocrinol Metab; 2018 Jan; 103(1):271-280. PubMed ID: 29099939
[TBL] [Abstract][Full Text] [Related]
25. Improving management of severe hypoparathyroidism: a case series.
Ugalde-Abiega B; Lamas Oliveira C; Alfaro Martínez JJ; Meizoso-Pita O; Sevillano Collantes C; Gomez García I; Perez Rodríguez A; Huguet I
Hormones (Athens); 2022 Mar; 21(1):71-77. PubMed ID: 34647284
[TBL] [Abstract][Full Text] [Related]
26. [PTH-replacement therapy in hypoparathyroidism : what benefits ?].
Trombetti A; Bégin MJ
Rev Med Suisse; 2021 Apr; 17(735):788-792. PubMed ID: 33881242
[TBL] [Abstract][Full Text] [Related]
27. Chronic hypoparathyroidism and treatment with teriparatide.
Marcucci G; Masi L; Cianferotti L; Giusti F; Fossi C; Parri S; Gronchi G; Brandi ML
Endocrine; 2021 Apr; 72(1):249-259. PubMed ID: 33538953
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone.
Rejnmark L
Endocrinol Metab (Seoul); 2024 Apr; 39(2):262-266. PubMed ID: 38572533
[TBL] [Abstract][Full Text] [Related]
29. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
30. Treatment options in hypoparathyroidism.
Sakane EN; Vieira MCC; Vieira GMM; Maeda SS
Arch Endocrinol Metab; 2022 Nov; 66(5):651-657. PubMed ID: 36382754
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA; Rubin MR; Schwarz P; Vokes T; Shoback DM; Gagnon C; Palermo A; Marcocci C; Clarke BL; Abbott LG; Hofbauer LC; Kohlmeier L; Pihl S; An X; Eng WF; Smith AR; Ukena J; Sibley CT; Shu AD; Rejnmark L
J Bone Miner Res; 2023 Jan; 38(1):14-25. PubMed ID: 36271471
[TBL] [Abstract][Full Text] [Related]
32. Hypoparathyroidism.
Mannstadt M; Bilezikian JP; Thakker RV; Hannan FM; Clarke BL; Rejnmark L; Mitchell DM; Vokes TJ; Winer KK; Shoback DM
Nat Rev Dis Primers; 2017 Aug; 3():17055. PubMed ID: 28857066
[TBL] [Abstract][Full Text] [Related]
33. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.
Sikjaer T; Rejnmark L; Rolighed L; Heickendorff L; Mosekilde L;
J Bone Miner Res; 2011 Oct; 26(10):2358-70. PubMed ID: 21773992
[TBL] [Abstract][Full Text] [Related]
34. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.
Khan AA; Rejnmark L; Rubin M; Schwarz P; Vokes T; Clarke B; Ahmed I; Hofbauer L; Marcocci C; Pagotto U; Palermo A; Eriksen E; Brod M; Markova D; Smith A; Pihl S; Mourya S; Karpf DB; Shu AD
J Clin Endocrinol Metab; 2022 Jan; 107(1):e372-e385. PubMed ID: 34347093
[TBL] [Abstract][Full Text] [Related]
35. Effects on calcium homeostasis of changing PTH replacement therapy of postoperative hypoparathyroidism from intact PTH to teriparatide: a case series.
Bislev LS; Sikjaer T; Rejnmark L
Calcif Tissue Int; 2014 Oct; 95(4):374-81. PubMed ID: 25086672
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
Mannstadt M; Clarke BL; Bilezikian JP; Bone H; Denham D; Levine MA; Peacock M; Rothman J; Shoback DM; Warren ML; Watts NB; Lee HM; Sherry N; Vokes TJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5136-5147. PubMed ID: 31369089
[TBL] [Abstract][Full Text] [Related]
37. Quality of life in hypoparathyroidism.
Vokes T
Bone; 2019 Mar; 120():542-547. PubMed ID: 30261328
[TBL] [Abstract][Full Text] [Related]
38. A New Era for Chronic Management of Hypoparathyroidism: Parathyroid Hormone Peptides.
Marcucci G; Brandi ML
Front Horm Res; 2019; 51():165-171. PubMed ID: 30641529
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.
Puig-Domingo M; Díaz G; Nicolau J; Fernández C; Rueda S; Halperin I
Eur J Endocrinol; 2008 Nov; 159(5):653-7. PubMed ID: 18703565
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in understanding and managing hypoparathyroidism.
Rubin MR
F1000Res; 2020; 9():. PubMed ID: 32765831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
